Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Corresponding Author
Shivani Garg
University of Wisconsin School of Medicine and Public Health, Madison
Address correspondence to Shivani Garg, MD, MS, University of Wisconsin–Madison, 1685 Highland Avenue, MFCB #4122, Madison, WI 53705. Email: [email protected].
Search for more papers by this authorRachna Unnithan
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorKaren E. Hansen
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorNathalie Costedoat-Chalumeau
AP-HP, Cochin University Hospital and Université de Paris, CRESS, INSERM, INRA, F-75004 Paris, France
Search for more papers by this authorChristie M. Bartels
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorCorresponding Author
Shivani Garg
University of Wisconsin School of Medicine and Public Health, Madison
Address correspondence to Shivani Garg, MD, MS, University of Wisconsin–Madison, 1685 Highland Avenue, MFCB #4122, Madison, WI 53705. Email: [email protected].
Search for more papers by this authorRachna Unnithan
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorKaren E. Hansen
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorNathalie Costedoat-Chalumeau
AP-HP, Cochin University Hospital and Université de Paris, CRESS, INSERM, INRA, F-75004 Paris, France
Search for more papers by this authorChristie M. Bartels
University of Wisconsin School of Medicine and Public Health, Madison
Search for more papers by this authorAbstract
Objective
Despite the pivotal role that hydroxychloroquine (HCQ) plays in treating systemic lupus erythematosus (SLE), less than 50% of patients take HCQ as prescribed. Measurement of HCQ blood levels can help clinicians distinguish nonadherence versus lack of efficacy of HCQ. Our objective was to systematically review publications and perform a meta-analysis to examine the correlation between HCQ levels and 1) nonadherence and 2) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, in SLE.
Methods
A comprehensive search was performed. We included observational and interventional studies that measured HCQ levels and assessed adherence or SLEDAI scores in adults with SLE. Forest plots compared pooled estimates of correlations between HCQ levels and reported nonadherence or SLEDAI scores.
Results
Among 604 studies screened, 17 were reviewed. We found 3-times higher odds of reported nonadherence in patients with low HCQ levels (odds ratio 2.95 [95% confidence interval (95% CI) 1.63, 5.35], P < 0.001). The mean SLEDAI score was 3.14 points higher in groups with below-threshold HCQ levels on a priori analysis (δ = 3.14 [95% CI –0.05, 6.23], P = 0.053), and 1.4 points higher in groups with HCQ levels of <500 ng/ml (δ = 1.42 [95% CI 0.07, 2.76], P = 0.039). Among 1,223 patients, those with HCQ levels ≥750 ng/ml had a 58% lower risk of active disease, and their SLEDAI score was 3.2 points lower.
Conclusion
We found a strong association between low HCQ levels and reported nonadherence. Our results suggest that HCQ levels of ≥750 ng/ml might be a potential therapeutic target.
Supporting Information
| Filename | Description |
|---|---|
| acr24155-sup-0001-FigS1.docxWord document, 43.9 KB | Fig S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–8.
- 2Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013; 40: 831–41.
- 3Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863–8.
- 4Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80–5.
- 5Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017; 44: 1032–8.
- 6Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168–72.
- 7Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 736–45.
- 8Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.
- 9Mehat P, Atiquzzaman M, Esdaile JM, Aviña-Zubieta A, De Vera MA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2017; 69: 1706–13.
- 10Feldman CH, Collins J, Zhang Z, Subramanian SV, Solomon DH, Kawachi I, et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 2018; 48: 205–13.
- 11Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther 2018; 103: 1074–82.
- 12Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 821–4.
- 13Dobbels F, Berben L, De Geest S, Drent G, Lennerling A, Whittaker C, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation 2010; 90: 205–19.
- 14Feldman CH, Zhang Z, Desai RJ, Lin T, Collins J, Subramanian SV, et al. Association between hydroxychloroquine nonadherence and adverse outcomes among patients with systemic lupus erythematosus [abstract]. Annual Scientific Meeting of the American College of Rheumatology, San Diego, CA, November 2017.
- 15Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015; 67: 1712–21.
- 16Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol 2016; 74: 693–9.
- 17Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus 2018; 27: 847–52.
- 18Arnaud L, Zahr N, Costedoat-Chalumeau N, Amoura Z. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev 2011; 10: 674–8.
- 19Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 2015; 42: 2092–7.
- 20Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284–90.
- 21Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013; 72: 1786–92.
- 22Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
- 23Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 24Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
- 25Viswanathan M, Patnode CD, Berkman ND, Bass EB, Chang S, Hartling L, et al. Assessing the risk of bias in systematic reviews of health care interventions: methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2008.
- 26Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–91.
- 27Geraldino-Pardilla L, Perel-Winkler A, Miceli J, Neville K, Danias G, Nguyen S, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus 2019; 28: 862–7.
- 28Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 2176–84.
- 29Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant 2018; 33: 1604–10.
- 30Iudici M, Pantano I, Fasano S, Pierro L, Charlier B, Pingeon M, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus 2018; 27: 265–72.
- 31Jolly M, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al. Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. Lupus 2016; 25: 735–40.
- 32Lee JY, Lee J, Kwok SK, Ju JH, Park KS, Park SH. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 536–42.
- 33Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken) 2016; 68: 1295–302.
- 34Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit 2016; 38: 259–67.
- 35Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012; 39: 174–9.
- 36Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
- 37Carmichael SJ, Day RO, Tett SE. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 2013; 43: 547–53.
- 38Francès C, Anne Cosnes MD, Pierre Duhaut MD, Zahr N, Boutros Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 479–84.
- 39Sleath B, Chewning B, de Vellis BM, Weinberger M, de Vellis RF, Tudor G, et al. Communication about depression during rheumatoid arthritis patient visits. Arthritis Rheum 2008; 59: 186–91.
- 40Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 2013; 65: 1421–9.
- 41Costedoat-Chalumeau N, Le Guern V, Piette JC. Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et al [letter]. Arthritis Rheumatol 2014; 66: 770.
- 42Mushlin AI, Appel FA. Diagnosing potential noncompliance: physicians' ability in a behavioral dimension of medical care. Arch Intern Med 1977; 137: 318–21.
- 43Yazdany J, Marafino BJ, Dean ML, Bardach NS, Duseja R, Ward MM, et al. Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation. Arthritis Rheumatol 2014; 66: 2828–36.
- 44Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? [editorial]. Arthritis Rheum 2006; 54: 3068–70.
- 45Costedoat-Chalumeau N, Le Guern V, Piette JC. Routine hydroxy-chloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood. J Rheumatol 2015; 42: 1997–9.
